Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells

Nature Communications

Volumn 5, Issue , 2014, Pages

  Hartmann, Felix J ^a   Khademi, Mohsen ^b   Aram, Jehan ^c   Ammann, Sandra ^a   Kockum, Ingrid ^b   Constantinescu, Cris ^c   Gran, Bruno ^c   Piehl, Fredrik ^b   Olsson, Tomas ^b   Codarri, Laura ^a   Becher, Burkhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; IL2RA PROTEIN, HUMAN; STAT5 PROTEIN;

DISEASE PREVALENCE; GENE EXPRESSION; GENOME; HEALTH IMPACT; POLYMORPHISM; RISK FACTOR;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC RISK; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOGENETICS; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; METABOLISM; MONONUCLEAR CELL; NORMAL HUMAN; PHOSPHORYLATION; T LYMPHOCYTE;

ANIMALIA;

CELL PROLIFERATION; FLOW CYTOMETRY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEALTHY VOLUNTEERS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; MULTIPLE SCLEROSIS; PHOSPHORYLATION; POLYMORPHISM, GENETIC; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84923369912     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6056     Document Type: Article

References (36)

1. Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9, 516-526 (2008).
2. Compston, A., & Coles, A. Multiple sclerosis. Lancet 372, 1502-1517 (2008).
3. Sawcer, S. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214-219 (2011).
4. Couturier, N. et al. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 134, 693-703 (2011).
5. Gregory, A. P. et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508-511 (2012).
6. Lundstrom, W. et al. Soluble IL7Ralpha potentiates IL-7 bioactivity and promotes autoimmunity. Proc. Natl Acad. Sci. USA 110, E1761-E1770 (2013).
7. Codarri, L. et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12, 560-567 (2011).
8. El-Behi, M. et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1-And IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12, 568-575 (2011).
9. McQualter, J. L. et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 194, 873-882 (2001).
10. Ponomarev, E. D. et al. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J. Immunol. 178, 39-48 (2007).
11. Burdach, S. et al. Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor. J. Clin. Invest. 87, 2114-2121 (1991).
12. Kruger, M. et al. Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1 beta. Immunology 88, 49-54 (1996).
13. Rochman, Y., Spolski, R., & Leonard, W. J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 9, 480-490 (2009).
14. Bielekova, B. et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl Acad. Sci. USA 101, 8705-8708 (2004).
15. Rose, J. W. et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69, 785-789 (2007).
16. Hafler, D. A. et al. Risk alleles for multiple sclerosis identified by a genomewide study. New Engl. J. Med. 357, 851-862 (2007).
17. International Multiple Sclerosis Genetics Consortium. Analysis of immunerelated loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45, 1353-1360 (2013).
18. Nelson, E. A. et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117, 3421-3429 (2011).
19. Vignali, D. A., Collison, L. W., & Workman, C. J. How regulatory T cells work. Nat. Rev. Immunol. 8, 523-532 (2008).
20. Viglietta, V., Baecher-Allan, C., Weiner, H. L., & Hafler, D. A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971-979 (2004).
21. Carbone, F. et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat. Med. 20, 69-74 (2014).
22. Burmester, G. R. et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-Alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann. Rheum. Dis. 70, 1542-1549 (2011).
23. Becher, B. et al. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann. Neurol. 45, 247-250 (1999).
24. Jamshidian, A., Shaygannejad, V., Pourazar, A., Zarkesh-Esfahani, S. H., & Gharagozloo, M. Biased Treg/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. J. Neuroimmunol. 262, 106-112 (2013).
25. Ram, M., Sherer, Y., & Shoenfeld, Y. Matrix metalloproteinase-9 and autoimmune diseases. J. Clin. Immunol. 26, 299-307 (2006).
26. Lycke, J. N., Karlsson, J. E., Andersen, O., & Rosengren, L. E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64, 402-404 (1998).
27. Dendrou, C. A. et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 41, 1011-1015 (2009).
28. Mohme, M. et al. HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. Brain 136, 1783-1798 (2013).
29. Becher, B., & Segal, B. M. T(H)17 cytokines in autoimmune neuroinflammation. Curr. Opin. Immunol. 23, 707-712 (2011).
30. Behrens, F. et al. MOR103, a human monoclonal antibody to granulocytemacrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2013-204816 (2014).
31. Noster, R. et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 6, 241ra280 (2014).
32. Lowe, C. E. et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39, 1074-1082 (2007).
33. Maier, L. M. et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5, e1000322 (2009).
34. Maier, L. M. et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J. Immunol. 182, 1541-1547 (2009).
35. de Bakker, P. I. et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat. Genet. 38, 1166-1172 (2006).
36. Khademi, M. et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS ONE 8, e63172 (2013).